Screener
PTC Therapeutics PTCT Inventories
Inventories at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $833,986 | $984,648 |
| Marketable securities | 1,058,477 | 960,723 |
| Trade and royalty receivables, net | 219,919 | 181,621 |
| Inventory, net | 75,567 | 79,647 |
| Prepaid expenses and other current assets | 66,054 | 67,309 |
| Total current assets | 2,254,003 | 2,273,948 |
| Fixed assets, net | 52,739 | 55,371 |
| Intangible assets, net | 380,684 | 388,753 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's inventories?
- PTC Therapeutics (PTCT) reported inventories of $75.57M in Q1 2026.
- How has PTC Therapeutics's inventories changed year-over-year?
- PTC Therapeutics's inventories increased by 248.6% year-over-year, from $21.68M to $75.57M.
- What is the long-term trend for PTC Therapeutics's inventories?
- Over 5 years (2020 to 2025), PTC Therapeutics's inventories has grown at a 33.6% compound annual growth rate (CAGR), from $18.7M to $79.65M.
- What does inventories mean?
- Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.
Ask your AI about PTC Therapeutics's inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude